Edouard L. Fu

Postdoc @BrighamWomens & @harvardmed
Editor @NDTsocial
My research: cardiorenal epidemiology, pharmacoepi, causal inference, trial emulation

[Edouard L. Fu @FuEdouard]

Why did observational studies find ⬆️survival for late dialysis initiation, whereas the IDEAL RCT found no difference? Was it confounding, the usual culprit we point to? No!

Our new paper @bmj_latest addresses this and much more! #epitwitter #nephtwitter
https://t.co/rILigIojR1

[AJKD @AJKDonline]

Care Processes and Clinical Responses to Newly Detected Albuminuria: The Stockholm Creatinine Measurements (SCREAM) Project

https://t.co/6hby9hx96I (OPEN ACCESS)

@AntoineCreon @meg21212 @FuEdouard @jjcarrero1

[The BMJ @bmj_latest]

Research methods and reporting: How to align eligibility and treatment assignment at time zero when emulating a target trial.

This article provides methodological guidance when emulating a target trial with longitudinal observational data
@FuEdouard
https://t.co/8vxczaTkil

[Ash Paul @pash22]

Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial
https://t.co/8qjcIjBPSi via @FuEdouard et al

[The BMJ @bmj_latest]

While target trial emulation cannot remove bias from inadequate data, it eliminates common biases induced by an incorrect design.

This article provides methodological guidance when emulating a target trial with longitudinal observational data
@FuEdouard
https://t.co/8vxczaTkil

[Ash Paul @pash22]

Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial
https://t.co/8qjcIjBPSi via @FuEdouard et al @RWJE_BA

[Edouard L. Fu @FuEdouard]

🔹 Publish in top journals & shape global guidelines
🔹 Supportive, collaborative team + strong mentorship

👉 PhD 1 - MD background: https://t.co/eFoGPpBNHD
👉 PhD 2 - Data science/(Bio)statistics/Epidemiology background: https://t.co/TezL6bpB5u

[Edouard L. Fu @FuEdouard]

📢 We’re hiring 2 PhD candidates @LUMC!

Help transform patient care by personalizing treatments for cardio‑kidney‑metabolic diseases using big data & causal inference.

We offer
🔹 Data from >20M patients
🔹 Cutting‑edge causal & ML methods
🔹 Collaborate w/ Karolinska & UCSF

[AJKD @AJKDonline]

Trends in Major Cardiovascular Events and Bleeding Among Patients With Advanced CKD: A Nationwide Swedish Study

@meg21212 @FuEdouard @karin_modig @jjcarrero1

https://t.co/8aqxjiMady #OpenAccess

[Antoine Créon @AntoineCreon]

1/9🚨 Changing one formula could make 38% more people “have CKD” overnight.
That’s what happens if we replace the CKD-EPI equation with EKFC in a European health system.
👉 Our @NDTsocial paper https://t.co/eb6fooBSo6
#CKD #GFR #nephtwitter
@jjcarrero1 @FuEdouard @PStoneOftheYear

[AJKD @AJKDonline]

Discordances Between Creatinine- and Cystatin C–Based Estimated GFR and Adverse Clinical Outcomes in Routine Clinical Practice

https://t.co/GznpwQ9ndv #OpenAccess

@jjcarrero1 @FuEdouard @Shoshana_Ballew @CarlElinder @LAInker @ASLtufts @meg21212

[Kevin Patrick Murphy @sirbayes]

Finally, a good modern book on causality for ML: https://t.co/jsHdpOEb96 by @eliasbareinboim. This looks like a worthy successor to the ground breaking book by @yudapearl which I read in grad school. (h/t @JoshuaSafyan for the ref).

[Antoine Créon @AntoineCreon]

🧵1/9
Could we improve kidney care by rethinking who gets referred to a nephrologist?
Our latest study from the SCREAM cohort suggests: yes — if we base it on predicted risk rather than fixed eGFR/ACR cutoffs.
📄 Caldinelli et al, 2025, @NDTsocial
🔗https://t.co/xVcR8LEnhn

[AJKD @AJKDonline]

Systemic Inflammation and the Risks of Adverse Kidney Outcomes in Adults With Atherosclerotic Cardiovascular Disease

https://t.co/j3FsXmiSvo #OpenAccess

#VisualAbstract

@FuEdouard @VladoPerkovic @KatherineTuttl8 @jjcarrero1

[Muthu Vaduganathan @mvaduganathan]

#GDMT has now arrived for #HFpEF

#SGLT2i (class I) and #nsMRA (class IIa) recommendations in initial global guidelines

https://t.co/PToRoHmz4D

#HeartFailure2025

[Edouard L. Fu @FuEdouard]

The 24th Sounds and Science concert features:
🎼 Mozart’s Marriage of Figaro & Violin Sonata
🎼 Dvořák’s Sonatina & Slavonic Dance No. 2
🎙️ With talks on kidney immunology & the composers' lives by @PRomagnani

Hosted by nephrologists @EllerKathrin & @RainerOberbauer

[Edouard L. Fu @FuEdouard]

🎶 Attending #ERA2025 in Vienna?
Don't miss Music & Kidney — a unique evening where classical music meets nephrology!

🗓️ Wednesday June 4 | 🕘 21:00 | 📍 Sofiensäle

🔗https://t.co/HYHeAcCdcM

@ERAkidney @jjcarrero1 #MusicAndMedicine #Nephrology #ViennaEvents

[Muthu Vaduganathan @mvaduganathan]

*30 years* after the start of the RALES trial

the targeting of the MR axis remains one of the hottest areas of drug development across cardio-kidney-metabolism

Expected read-outs in '25:
#ACHIEVE sMRA in ESKD
#CONFIDENCE Combo nsMRA+SGLT2i in CKD
#SPIRITHF sMRA in HFmrEF/HFpEF

[Muthu Vaduganathan @mvaduganathan]

🔥 #CONFIDENCE closed out & selected as LBCT to headline #ERA25, led by #ProfRajivAgarwal

Largest RCT to test combination #SGLT2i empagliflozin & #nsMRA finerenone

Will 1+1 = 2?

Baseline: https://t.co/agxeIEENNp

Design: https://t.co/AzSH6JfVem

See you in Vienna 🇦🇹 @ERAkidney

[Antoine Créon @AntoineCreon]

Causal inference in observational studies can be tricky. We discuss key methodological considerations from a recent study in JASN @asnpublications. With @FuEdouard and @jjcarrero1. Read it here: https://t.co/YOEXvVnxMe

[AJKD @AJKDonline]

Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study

https://t.co/KUwX4mYG4F #OpenAccess

@ELambourg @FuEdouard @C_H_Grant @johnrpetrie @SamiraBell76 #VisualAbstract #CKD